Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HINT1 | P49773 | 5/20 | 0.69 |
| ▸ | NT5E | P21589 | 1/20 | 0.69 |
| ▸ | TGM2 | P21980 | 1/20 | 0.64 |
| ▸ | GSK3A | P49840 | 2/20 | 0.62 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.62 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.62 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.61 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.61 |
| ▸ | KRAS | P01116 | 8/20 | 0.60 |
| ▸ | PNP | P00491 | 1/20 | 0.60 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6863972 | 0.92 | HINT1 (0.68) | HINT1NT5ETGM2GSK3ARPS6KA3 | |
| SCHEMBL7098413 | 0.91 | HINT1 (0.67) | HINT1NT5ETGM2GSK3ARPS6KA3 | |
| SCHEMBL6239924 | 0.91 | HINT1 (0.73) | HINT1NT5ETGM2GSK3ARPS6KA3 | |
| 2'-Beta-Methyl-Guanosine SCHEMBL383785 | 0.91 | HINT1 (0.75) | HINT1NT5ETGM2GSK3ARPS6KA3 | |
| 2'-Beta-Methyl-Guanosine SCHEMBL15338533 | 0.91 | HINT1 (0.75) | HINT1NT5ETGM2GSK3ARPS6KA3 | |
| 2'-Beta-Methyl-Guanosine SCHEMBL11965261 | 0.91 | HINT1 (0.75) | HINT1NT5ETGM2GSK3ARPS6KA3 | |
| 2'-Beta-Methyl-Guanosine SCHEMBL116165 | 0.91 | HINT1 (0.75) | HINT1NT5ETGM2GSK3ARPS6KA3 | |
| 2'-Beta-Methyl-Guanosine SCHEMBL14178410 | 0.91 | HINT1 (0.75) | HINT1NT5ETGM2GSK3ARPS6KA3 | |
| SCHEMBL5501200 | 0.91 | HINT1 (0.69) | HINT1NT5ETGM2GSK3ARPS6KA3 | |
| SCHEMBL6826563 | 0.90 | HINT1 (0.68) | HINT1NT5ETGM2GSK3ARPS6KA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026103932-A1 | INHIBIN SUBUNIT βE INHIBITOR AND USE THEREOF | 成都迪合永欣医药科技有限公司 | 2026-05-21 | — | — | WO | disclosed |
| US-20110257244-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES AND SMALL MOLECULES FOR USE IN REDUCING MICRO RNA ACTIVITY LEVELS AND USES THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| WO-2009091972-A2 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES AND SMALL MOLECULES FOR USE IN REDUCING MICRO RNA ACTIVITY LEVELS AND USES THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-07-23 | — | — | WO | disclosed |
| US-6800751-B2 | ALKYLATION OF 2'-HYDROXY GROUP OF RIBONUCLEOSIDE PROTECTED WITH INVENTIVE SILYLATING AGENTS IN PRESENCE OF EXCESS OF MILD HINDERED BASE MAY BE CARRIED OUT WITHOUT PROTECTING EXOCYCLIC AMINE AND OXO FUNCTIONALITIES OF NUCLEOBASES | ISIS PHARMACEUTICALS, INC. | 2004-10-05 | — | — | US | disclosed |
| US-20030225262-A1 | Reagent and process for protecting active groups | IONIS PHARMACEUTICALS, INC. | 2003-12-04 | — | — | US | disclosed |
| WO-2003087053-A2 | REAGENT AND PROCESS FOR PROTECTING NUCLEOSIDE ACTIVE GROUPS | ISIS PHARMACEUTICALS, INC. (US) | 2003-10-23 | — | — | WO | disclosed |
| EP-1090137-A1 | PRODUCTION OF POLYMERS FROM NUCLEOTIDIC AND/OR NON-NUCLEOTIDIC ELEMENTS USING ENZYMATIC METHODS | Larova Biochemie GmbH (DE) | 2001-04-11 | — | — | EP | disclosed |
| WO-1999067413-A1 | PRODUCTION OF POLYMERS FROM NUCLEOTIDIC AND/OR NON-NUCLEOTIDIC ELEMENTS USING ENZYMATIC METHODS | LAROVA BIOCHEMIE GMBH (DE) | 1999-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257244-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES AND SMALL MOLECULES FOR USE IN REDUCING MICRO RNA ACTIVITY LEVELS AND USES THEREOF | AGO2, BCDIN3D, TRDMT1 | HINT1 3463/4885NT5E 344/4885TGM2 3807/4885 |
| US-20030225262-A1 | Reagent and process for protecting active groups | TRDMT1, SBDS, DIMT1 | HINT1 556/4885NT5E 1193/4885TGM2 3831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.